Introduction:
High dividend-yielding pharma stocks offer regular income, portfolio stability, and resilience during market volatility. These stocks are ideal for conservative investors seeking steady returns, especially in the healthcare sector known for consistent demand and long-term growth potential.
Novartis India Ltd:
With a dividend yield of 3.18%, this pharma stock offers a compelling mix of stability and income for long-term investors. Trading at ₹786.15, it balances decent returns with a P/E of 22.50 in the healthcare sector.
On April 17, 2025, Novartis India Ltd opened at ₹823.95, reaching a high of ₹824.00, up 0.31% from the previous close of ₹817.50 and a low of ₹810.00. The stock closed at ₹820.00, with a market cap of ₹2,024.65 Crores.
Novartis India Ltd (BSE: 500672) is a leading pharmaceutical company engaged in the manufacture and marketing of healthcare solutions across therapeutic areas. It operates as a subsidiary of the global Novartis Group, offering high-quality, innovative medicines to Indian patients.
Also Read: Stock jumps 6% after receiving order worth ₹348 Cr from Tamil Nadu Medical Services Corp.
Denis Chem Lab Ltd:
Offering a dividend yield of 2.65%, this affordable pharma stock is priced at ₹94.34 with a low P/E of 12.96. It provides value-based exposure to dividend-seeking investors in the pharmaceutical segment with moderate risk.
On April 17, 2025, Denis Chem Lab Ltd opened at ₹99.44, reaching a high of ₹105.00, up 1.62% from the previous close of ₹98.37 and a low of ₹98.98. The stock closed at ₹99.96, with a market cap of ₹138.71 Crores.
Denis Chem Lab Ltd (BSE: 537536) specializes in manufacturing parenteral drugs and IV fluids. With decades of expertise in healthcare formulations, the company serves hospitals and medical institutions across India, focusing on quality production and regulatory compliance in sterile product segments.
Also Read: Green energy stock under ₹60 jumps after receiving order from Sunsure Energy
Alivus Life Sciences Ltd:
This high-cap pharma player provides a 2.33% dividend yield with a P/E of 26.78. Priced at ₹965.30, it presents a strong dividend payout history, attracting investors interested in reliable income from the healthcare sector.
On April 17, 2025, Alivus Life Sciences Ltd opened at ₹1,001.90, reaching a high of ₹1,007.90, and a low of ₹986.20, down 1.30% from the previous close of ₹1,000.50. The stock closed at ₹987.50, with a market cap of ₹12,100.53 Crores.
Alivus Life Sciences Ltd (NSE: ALIVUS) is a prominent name in the pharmaceutical industry, known for its advanced formulation and manufacturing capabilities. The company delivers high-quality, affordable medicines and is committed to innovation across various therapeutic categories, including chronic and acute care.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
